COMPASS Pathways rebounds on earnings after selloff driven by rival's NDA submission

What happened

COMPASS Pathways traded higher in premarket trading on Tuesday after its Q3 2026 results eased investor concerns, following a sharp selloff in the previous session triggered by a report that Usona Institute filed a new drug application for its psilocybin therapy.

Confirmed

Global impact / market context

A rival filing first could let Usona reach patients and set pricing and safety rules earlier, which means Compass may face a tougher launch for COMP360, planned for the first half of 2027. Its results reassured investors that its own program remains on track.

Analyst inference

The selloff hit Compass and peers Helus Pharma, Definium and GH Research together, showing investors treat psychedelic drug approvals as one shared race. Compass and Usona both hold a priority voucher, which means faster review, so timing of approval and launch now drives how investors position.

Analyst inference

What to watch

1. Compass said in July it plans to complete its rolling NDA submission for COMP360 in the fourth quarter of 2026, targeting treatment-resistant depression, with a market rollout expected in the first half of 2027. Confirmed
2. Usona's filing implies a possible approval at the end of 2026 or early 2027, and it could theoretically be first to set pricing and REMS, which means safety rules for prescribing. Proposed
3. Watch whether Compass keeps its submission and launch timeline and whether Usona's earlier approval shifts pricing and safety-rule terms, which would affect Compass revenue and costs. Analyst inference

Evidence

• seekingalpha.com